Oppenheimer Thinks Prevail Therapeutics’ Stock is Going to Recover

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Prevail Therapeutics (PRVLResearch Report), with a price target of $25.00. The company’s shares closed last Friday at $9.76, close to its 52-week low of $9.02.

According to TipRanks.com, Olson is a 1-star analyst with an average return of -0.6% and a 42.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Frequency Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Prevail Therapeutics with a $25.50 average price target.

See today’s analyst top recommended stocks >>

Based on Prevail Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $22.1 million. In comparison, last year the company had a GAAP net loss of $15.1 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson’s disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.